STDs

The firm will use funds from the round, led by the Midlands Engine Investment Fund, to develop its optical point-of-care diagnostic testing platform.

Cambridge, UK-based Sense Biodetection will use the funding to develop a portfolio of instrument-free, point-of-care molecular diagnostic tests.

The company said that the decline in revenues reflected lower industry-wide reimbursement rates under PAMA.

The test is the first near-patient assay for M. genitalium, and can also guide treatment by detecting antibacterial resistance markers.

The firm said its platform provides sample-to-answer results for two of the most frequently tested sexually transmitted infections, enabling rapid testing and treatment.

Formerly known as Diassess, the Emeryville, California-based startup will use the funding to finance regulatory clearances and early commercialization.

Danaher's life sciences revenues grew 6 percent, while its diagnostics revenues rose nearly 5 percent, including an increase of more than 20 percent at Cepheid.

The latest NYS Department of Health approval expands the company's CT/NG testing to samples from multiple relevant body sites.

The Cobas TV/MG test detects Trichomonas vaginalis (TV) and Mycoplasma genitalium (MG) DNA in symptomatic and asymptomatic patients.